Acadia Pharmaceuticals (ACAD) is back in focus after the firm reported that remlifanserin did not meet the primary endpoint in the Phase 2 RADIANT trial for Alzheimer’s disease psychosis, which has prompted a shareholder rights investigation.
The Phase 2 setback has fed into a sharp reset in sentiment, with Acadia Pharmaceuticals’ share price down 33.09% over the past 30 days and 29.17% year to date. The 1-year total shareholder return of an 8.55% decline and 3-year total shareholder return of a 20.43% decline point to fading longer term momentum, despite a modest 5.26% total shareholder gain over five years.
Reassess your biotech exposure after the Acadia Pharmaceuticals trial setback by scanning a curated group of 32 high quality undervalued stocks that have shown stronger recent share price support and more resilient sentiment profiles.
Acadia Pharmaceuticals now trades after a steep reset in expectations, with fresh trial risk colliding with ongoing revenue and profit generation. Does that tilt the balance of risk and potential reward toward buyers, or call for more patience in the valuation work that follows?
Most Popular Narrative: 42% Undervalued
Against Acadia Pharmaceuticals' last close of $18.62, the most followed narrative points to a fair value of $32.16 based on a 7.55% discount rate. This frames a wide gap between modeled worth and current trading levels.
The analysts have a consensus price target of $32.16 for Acadia Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $49.0, and the most bearish reporting a price target of just $17.0.
See why 57 investors see Acadia Pharmaceuticals as 42% undervalued.
Result: Fair Value of $32.16 (UNDERVALUED)
Still, the whole Acadia Pharmaceuticals story wobbles if confidence in remlifanserin erodes further or if DAYBUE and NUPLAZID fall short of projected sales ramps.
Find out about the key risks to this Acadia Pharmaceuticals narrative.
Next Steps
Mixed about the tone of the Acadia Pharmaceuticals story so far, with fresh trial disappointment set against existing products and future optionality. Move quickly to review both sides of the debate for yourself and weigh the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Acadia Pharmaceuticals?
Do not stop with Acadia Pharmaceuticals. Use this setback as a prompt to refresh your watchlist with stocks that better match your return goals and risk comfort.
- Target more resilient cash generators by scanning a list of solid balance sheet and fundamentals (25 results) that can better support operations through tough periods.
- Hunt for underappreciated quality by reviewing a focused 20 high quality undiscovered gems that many investors may still be overlooking.
- Dial down portfolio stress by filtering for 32 resilient stocks with low risk scores that score well on stability and downside protection.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com